NuvOx in the News

FDA Allows a Phase II Clinical Trial in Stroke for NuvOx Pharma’s DDFPe

PR Dot COM

The FDA has allowed an Investigational New Drug (IND) application to initiate a Phase II clinical trial in 60 stroke patients to proceed to test NuvOx’s investigational drug product, dodecafluoropentane emulsion (DDFPe). Read more...

NIH Awards Grant to NuvOx Pharma for Development of Field-ready Syringe for Oxygen Delivery Drug

NCI logo NuvOx Pharma has received a Phase I SBIR grant for $150,000 from the National Institutes of Health, specifically the National Institute of Neurological Diseases and Stroke (NINDS), for development of a novel syringe sonication device that may allow quick preparation of an investigational drug for oxygen delivery. For more information, read here.

NuvOx Wins TechConnect Defense Innovation Award

NCI logo Biotech drug startup NuvOx Pharma was awarded the 2017 TechConnect Defense Innovation Award based on the potential positive impact the submitted technology will have for the warfighter and national security. To learn more, visit: The Arizona Daily Star.

NuvOx Pharma wins AZBio Fast Lane Award

AZBio Awards Video from NuvOx Pharma on Vimeo.

NuvOx was honored with the AZBIO Fast Lane Award for the company's many achievements in the last 18 months. The award committee noted the company's advancements in clinical trials for brain cancer and stroke, the licensing agreement in hemorrhagic shock, and continued development in pre-clinical stage indications such as heart attack. A link to a press release is here: NuvOx wins AZBio Fast Lane Award

National Cancer Institute Awards $3M Grant to NuvOx Pharma for Phase II Clinical Trial in Brain Cancer

NCI logo The National Institutes of Health’s National Cancer Institute (NCI) has awarded a grant for up to $3 million to NuvOx Pharma to initiate a Phase II clinical trial for the investigational drug, NVX-108, in the brain cancer, glioblastoma multiforme (GBM). For more information, read here.

Breathing new life into an old drug.

MedCity News MedCity News Interviews NuvOx Pharma on its development history. Click here to read more!

NuvOx Wins MedCity INVEST Perfect Pitch Contest

MedCity INVEST NuvOx Pharma wins 1st place out of the biopharma companies at the MedCity INVEST Perfect Pitch Contest in Chicago. At the contest, promising startup companies, offering innovative approaches or trying to solve some of the biggest problems in healthcare pitched to investors live. Participating biopharma, diagnostics, medical device, and digital health startups have been pre-selected by a panel of venture capitalists and other investors.

BIO 2017 Innovation Zone Company Snapshot

BIONuvOx is interviewed by BIO 2017 Innovation Zone supported by the NIH. Read more here...

News Report on the Clinical Trial in Stroke for NVX-208

UAMS A TV News report on the clinical trial in stroke for NuvOx's drug NVX-208 at the University of Arkansas, interviewing Dr. Bill Culp. Click Here to Watch.

FDA allows NuvOx Pharma to run a Phase II Clinical Trial in Brain Cancer

PR Dot COM

The FDA has allowed an Investigational New Drug (IND) application to initiate a Phase II clinical trial for NuvOx Pharma’s oxygen therapeutic, NVX-108, in patients with the hypoxic solid brain tumor, glioblastoma multiforme (GBM). NVX-108 is an injectable drug that travels through the bloodstream arriving first at the lungs to pick up oxygen and finally to hypoxic tissue where it passively delivers the oxygen. It is designed to reduce tumor hypoxia in order to make tumors more sensitive to radiation therapy and chemotherapy. Read more...